Inflammation News and Research

RSS

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

i26 hyperimmune egg balances improper immune inflammatory response

Our immune systems are in a constant battle with foreign invaders to keep our bodies healthy. Outside forces like pollution, poor nutrition and new strains of disease keep our immune systems at an overly boosted or inflamed state, which affects energy levels, body and emotional health and overall quality of life. Through inflammatory immune cells, our bodies fight to defend us from this onslaught. Too few of these cells can result in illness, while too many could lead to a high immune response, resulting in heightened inflammation and collateral damage to the body's once-healthy tissues.

16 Jul 2010

New findings on macrophage activation can facilitate development of early diagnosis tools

Immune system cells called macrophages spring into action to surround and destroy threats such as viruses or cancer cells. But sometimes the would-be protective response leads to persistent inflammation, which, in turn, can cause disease.Scientists don't know exactly how macrophages cross the line from being good cops to bad cops, but researchers at the University of Florida recently unearthed several clues about the mechanisms involved. Through the lens of two inflammation-related diseases, HIV and rheumatoid arthritis, they identified changes in specific proteins linked to the action of macrophages, white blood cells that are key to the body's natural defenses.

16 Jul 2010

$235 million announced for expansion of biotech sector at CSL

A $235 million expansion of Australia's largest biotech facility in Melbourne is planned and this is expected to create hundreds of jobs. CSL biopharmaceutical research complex in Broadmeadows, in the north of Melbourne will be receiving this financial aid from both the State as well as Federal government over a five year investment plan. This will create an estimated 320 temporary construction jobs and later 333 new highly-skilled medical research openings by 2018.

15 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Plexxikon announces promising preclinical data of PLX3397

Plexxikon Inc. today announced promising preclinical data from in vivo Alzheimer's Disease studies demonstrating a dramatic reduction in activated microglia in the brains of very old (22 months) 3xTG-AD mice, a triple transgenic model for Alzheimer's Disease. This reduction of activated microglia led to significantly improved learning in the treated group.

15 Jul 2010

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

The medical standard of care - comprised of surgery, radiation and chemotherapy - for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

15 Jul 2010

NIH announces 5 more years of funding for Consortium of Food Allergy Research

Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).

15 Jul 2010

Pre-clinical study results of EVP-0015962 presented at AAICAD 2010

EnVivo Pharmaceuticals today announced at the Alzheimer's Association 2010 International Conference on Alzheimer's Disease results from its proprietary gamma-secretase modulator pre-clinical study. In a transgenic mouse model, EnVivo's EVP-0015962 reduced amyloid plaque buildup which is believed to be a cause of Alzheimer's disease, reversed behavioral deficits and reduced brain inflammation associated with Alzheimer's disease.

15 Jul 2010

Over half of UK swine flu hospital admissions, deaths occurred in previously healthy people: Research

Over half of UK swine flu hospital admissions and inpatient deaths occurred in people with no underlying health problems or obvious risk factors, research at the University of Liverpool has found.

15 Jul 2010

University of Louisville ophthalmology professor receives $60,000 RPB Special Scholar Award

Qingxian Lu, PhD, assistant professor of ophthalmology and visual sciences at the University of Louisville School of Medicine, has received the $60,000 William and Mary Greve Special Scholar Award from the Research to Prevent Blindness (RPB) organization. The funds will go toward Lu's research in retinitis pigmentosa, a group of genetic disorders that can lead to night blindness, loss of peripheral vision and total blindness.

15 Jul 2010

Study links obesity to poorer memory, brain function in older women

The more an older woman weighs, the worse her memory, according to new research from Northwestern Medicine. The effect is more pronounced in women who carry excess weight around their hips, known as pear shapes, than women who carry it around their waists, called apple shapes.

15 Jul 2010

Study links high-fat diet as potential cause of prostatic diseases

Prostate cancer is the second leading cause of cancer-related deaths in men with an estimated 192,280 new cases diagnosed in the US in 2009 (Jemal 2009). Diet is considered one of the most important controllable risk factors for inflammation and prostate diseases including benign prostatic hyperplsia, prostatitis, and prostate cancer.

15 Jul 2010

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an Environmental Exposure Chamber model of allergic rhinitis caused by natural exposure to seasonal allergens.

14 Jul 2010

Highlights of AAPM 52nd meeting

The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.

14 Jul 2010

Silence Therapeutics extends ongoing research, development collaboration with AstraZeneca

Silence Therapeutics plc is pleased to announce a one-year extension of its ongoing research and development collaboration with AstraZeneca. Under the terms of the agreement, which has progressed well since being signed in July 2007, Silence and AstraZeneca are jointly collaborating in the identification and optimization of five novel siRNA therapeutic molecules addressing respiratory and oncology indications.

14 Jul 2010